In prostate carcinoma, the activity of Stat3 located on the Wnt3a promoter is inhibited by TGF-β, resulting in a reduction of Wnt3a levels in tissues and subsequent suppression of tumor progression [174]. This evidence concerns the gene WNT3A and prostate carcinoma.